secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001104659-22-028113
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist reports Q4 2021 net loss $36.9M; cash $326.9M; rusfertide Phase 3 to start Q1 2022
--------------------------------------------------------------------------------

- Net loss Q4 2021 $36.9M ($0.77/share) vs $18.9M ($0.48/share) in Q4 2020; full year loss $125.6M ($2.71/share) vs $66.2M ($1.92/share).
- Cash, equivalents and marketable securities $326.9M as of Dec 31, 2021; expected to fund operations through 2024.
- Phase 3 VERIFY study of rusfertide in polycythemia vera to initiate Q1 2022; topline PN-943 Phase 2 UC data expected Q2 2022.
- Phase 2b FRONTIER 1 study of PN-235 in plaque psoriasis initiated; $25M milestone due upon dosing third patient.
- R&D expenses Q4 2021 $38.4M (vs $19.5M); full year $126.0M (vs $74.5M) on advancing pipeline and employee costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465922028113/0001104659-22-028113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465922028113/tm227855d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-028113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer